Penicillamine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00859 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 13 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | megaloblastic anemia (disease) | KG + DL |
| 2 | tricarboxylic acid cycle disorder | KG + DL |
| 3 | disease of transporter activity | KG + DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 5 | glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form | KG + DL |
| 6 | glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form | KG + DL |
| 7 | adult polyglucosan body disease | KG + DL |
| 8 | granulomatous disease, chronic, X-linked | KG + DL |
| 9 | pyruvate metabolism disorder | KG + DL |
| 10 | anemia, nonspherocytic hemolytic, due to G6PD deficiency | KG + DL |
| 11 | inborn disorder of fatty acid oxidation and ketone body metabolism | KG + DL |
| 12 | disorder of mineral absorption and transport | KG + DL |
| 13 | hemolytic anemia due to diphosphoglycerate mutase deficiency | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.